<DOC>
	<DOCNO>NCT01437202</DOCNO>
	<brief_summary>This multicenter , retrospective , observational study validate pharmacogenetics model imatinib metabolism resistance patient chronic myeloid leukemia among patient different independent cohort .</brief_summary>
	<brief_title>Pharmacogenomics Validation Imatinib Chronic Myeloid Leukemia</brief_title>
	<detailed_description>1 . The activity Imatinib ( IM ) mediate block activity BCR/ABL tyrosine kinase CML cell . However , patient fail achieve optimal response , substantial proportion patient develop resistance IM . 2 . IM substrate adenosine triphosphate binding cassette ( ABC ) transporter , ABCB1 ABCG2 , active uptake IM cell mediate human organic cationic transporter-1 ( hOCT1 ) . Also , IM metabolize first pass drug metabolism cytochrome P450 - CYP3A4 CYP3A5 . In addition , deliver bound form plasma protein refer Î±1-acid glycoprotein ( AGP ) . 3 . Accordingly , intracellular systemic level imatinib influence factor ABCB1 , ABCG2 , hOCT1 , CYP3A4 , CYP3A5 AGP gene . Inter-individual variability 5 candidate gene associate drug transport/metabolism ( i.e . ABCB1 , ABCG2 , hOCT1 , CYP3A4/3A5 AGP ) could affect expression correspond protein , thus influence treatment outcome imatinib therapy . 4 . In investigator ' previous study , investigator report cumulative incidence MCyR CCyR significantly affect predictive model use 2 genotype disease stage . These predictive model CCyR/MMoR LOR/treatment failure seem work well . However , external validation predictive model warrant especially use ethnically different independent cohort .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Chronic myeloid leukemia stage include chronic phase , accelerate blastic phase . Age &gt; 18 year Complete set clinical data available review ( demographic data , stage , treatment history , cytogenetic report , late BCR/ABL RQPCR result ) Treated imatinib mesylate least 3 month Treated imatinib mesylate le 3 month Not agree intention study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>imatinib</keyword>
	<keyword>drug resistance</keyword>
	<keyword>pharmacogenetics</keyword>
</DOC>